KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
Merck announced that KEYTRUDA monotherapy met the primary endpoint of progression-free survival (PFS) compared to platinum doublet chemotherapy in the Phase 3 KEYNOTE-C93 trial for patients with dMMR advanced or recurrent endometrial cancer. This is the first Phase 3 trial to show improved PFS for a PD-1 inhibitor versus chemotherapy as a monotherapy in the frontline setting for this indication, potentially offering a new chemo-free option.
Key figures
- Drug Name
- KEYTRUDA (pembrolizumab)
- Phase Of Trial
- Phase 3
- Patients enrolled
- 299
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.